Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Octreotide in carcinoid syndrome

worth the extra cost

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Octreotide in carcinoid syndrome. Pharmacoecon. Outcomes News 195, 10 (1999).

    Download citation


    • Liver Metastasis
    • Octreotide
    • Vasoactive Intestinal Peptide
    • Carcinoid Tumour
    • Costly Agent